# Heartflow, Inc. (HTFL) > Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/heartflow-inc/ JSON: https://steadybase.io/company/heartflow-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026. ## Company - Legal name: Heartflow, Inc. - Ticker: HTFL (Nasdaq) - SEC CIK: 0001464521 - Industry: Surgical & Medical Instruments & Apparatus (SIC 3841) - Headquarters: San Francisco, CA - Fiscal year ends: December 31 - SEC filer category: Non-accelerated filer
Emerging growth company - Website: heartflow.com - LinkedIn: https://www.linkedin.com/company/heartflow-inc - Next earnings date: Nov 12, 2026 ## Key facts - Revenue: $176.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/0001464521-26-000042-index.html - Operating income: -$64.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/0001464521-26-000042-index.html - Net income: -$116.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/0001464521-26-000042-index.html - SG&A: $134.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/0001464521-26-000042-index.html - Employees: 843 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - Shares outstanding: 86,953,627 as of Jul 31, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000131/0001464521-26-000131-index.html - Auditor: Pricewaterhousecoopers LLP, San Jose, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm ## Business We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD. Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm ## Annual results | Fiscal year ended | Revenue | Operating income | Net income | SG&A | |---|---|---|---|---| | Dec 31, 2025 | $176.0M | -$64.1M | -$116.8M | $134.3M | | Dec 31, 2024 | $125.8M | -$61.2M | -$96.4M | $112.2M | | Dec 31, 2023 | $87.2M | -$72.9M | -$95.7M | $95.1M | Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/heartflow-inc.json ## Officers and directors - John C.M. Farquhar, Chief Executive Officer. LinkedIn: https://linkedin.com/in/john-farquhar-8819147. Source: Form 4 filed Sep 14, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000145/0001464521-26-000145-index.htm - Vikram Verghese, Chief Financial Officer. LinkedIn: https://linkedin.com/in/vikram-verghese-cfa-169a625. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000149/0001464521-26-000149-index.htm - Campbell Rogers, Chief Medical Officer. LinkedIn: https://linkedin.com/in/campbell-rogers-67952938. Source: Form 4 filed Sep 21, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000152/0001464521-26-000152-index.htm - Marie L. Jones, Chief Accounting Officer. Source: Form 4 filed Aug 10, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000123/0001464521-26-000123-index.htm - Mhairi L. Jones, Chief Accounting Officer. Source: 10-K filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - William C. Weldon, Chair of the Board of Directors. Source: 10-K filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - Casey M. Tansey, Director. Source: 10-K filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - Jeffrey C. Lightcap, Director. Source: 10-K filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - Julie A. Cullivan, Director. Source: 10-K filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - Timothy C. Barabe, Director. Source: 10-K filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - Campbell D.K. Rogers, M.D., Named in proxy. Source: DEF 14A filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1464521/000119312526189307/d54880ddef14a.htm ## Recent 8-K events - Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000129/htfl-20260813x8k.htm - Jun 18, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000081/htfl-20260616x8k.htm - May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000069/htfl-20260514x8k.htm - Mar 18, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000040/htfl-20260318x8k.htm - Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000005/htfl-20260112x8k.htm - Nov 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452125000018/htfl-20251112.htm - Sep 10, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452125000009/htfl-20250910.htm - Aug 25, 2025: Item 1.02, Termination of a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452125000005/htfl-20250822.htm - Aug 11, 2025: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1464521/000162828025039636/heartflow-8xkclosing.htm ## Insider trades (Form 4) - Oct 22, 2026: Campbell Rogers (Chief Medical Officer) sold 23,933 shares, about $1.3M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000156/0001464521-26-000156-index.htm - Oct 12, 2026: John C.M. Farquhar (Chief Executive Officer) sold 38,900 shares, about $1.9M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000154/0001464521-26-000154-index.htm - Sep 18, 2026: Campbell Rogers (Chief Medical Officer) sold 19,682 shares, about $987,052. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000152/0001464521-26-000152-index.htm - Sep 18, 2026: Vikram Verghese (Chief Financial Officer) sold 24,345 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000149/0001464521-26-000149-index.htm - Sep 15, 2026: Vikram Verghese (Chief Financial Officer) sold 34,975 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000147/0001464521-26-000147-index.htm - Sep 11, 2026: John C.M. Farquhar (Chief Executive Officer) sold 38,900 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000145/0001464521-26-000145-index.htm - Sep 8, 2026: Vikram Verghese (Chief Financial Officer) sold 6,640 shares, about $332,199. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000143/0001464521-26-000143-index.htm - Sep 3, 2026: Vikram Verghese (Chief Financial Officer) sold 33,416 shares, about $1.7M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000141/0001464521-26-000141-index.htm - Aug 21, 2026: John C.M. Farquhar (Chief Executive Officer) sold 27,230 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000139/0001464521-26-000139-index.htm - Aug 18, 2026: John C.M. Farquhar (Chief Executive Officer) sold 32,676 shares, about $1.5M. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000137/0001464521-26-000137-index.htm - Aug 17, 2026: Campbell Rogers (Chief Medical Officer) sold 9,219 shares, about $380,099. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000135/0001464521-26-000135-index.htm - Aug 14, 2026: John C.M. Farquhar (Chief Executive Officer) sold 15,560 shares, about $607,774. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000133/0001464521-26-000133-index.htm - Aug 10, 2026: John C.M. Farquhar (Chief Executive Officer) sold 22,562 shares, about $638,730. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000127/0001464521-26-000127-index.htm - Jul 15, 2026: Campbell Rogers (Chief Medical Officer) sold 9,219 shares, about $237,113. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000103/0001464521-26-000103-index.htm - Jul 10, 2026: John C.M. Farquhar (Chief Executive Officer) sold 22,562 shares, about $626,096. Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000101/0001464521-26-000101-index.htm ## What management said - "The second quarter reflects the growing strength of Heartflow's category leadership and unique AI technology platform for identifying, diagnosing, managing and treating coronary artery disease" John Farquhar, President and CEO of Heartflow (8-K filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000129/htfl-20260813xex99_1.htm ## Latest filings - 8-K filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000129/htfl-20260813x8k.htm - 10-K filed Mar 18, 2026: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm - 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000131/htfl-20260630x10q.htm - DEF 14A filed Apr 29, 2026: https://www.sec.gov/Archives/edgar/data/1464521/000119312526189307/d54880ddef14a.htm ## About this data SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from. Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/